3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pain, Postoperative
2
Pain
2
Multiple Myeloma
2
Carcinoma, Non-Small-Cell Lung
2
Agnosia
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Hematopoietic and Lymphatic System Neoplasm
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma in Situ
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
32
Vincristine
22
blinatumomab
20
Methotrexate
20
Specimen Handling
19
Prednisone
19
Cytarabine
17
merphos
16
prednylidene
15
deltacortene
15
Biopsy
15
Mercaptopurine
14
Doxorubicin
14
Dexamethasone
14
N,N-dicyclohexyl-isoborneol-10-sulfonamide
13
pegaspargase
12
azathiopurine
12
Rituximab
12
Etoposide
12
dexamethasone acetate
11
dexamethasone 21-phosphate
11
auricularum
11
Spinal Puncture
11
Calcium Dobesilate
11
Asparaginase
11
Leucovorin
10
fludarabine
9
Magnetic Resonance Spectroscopy
9
Inotuzumab Ozogamicin
9
Daunorubicin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Burkitt Lymphoma
×
Acetaminophen
×
90 days
×
Clear all
NCT07570173
2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
340 enrolled